These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 22261737

  • 21. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P.
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
    Dugel PU, Petrarca R, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.
    Ophthalmology; 2012 Jul; 119(7):1425-31. PubMed ID: 22465819
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M, Sharma S.
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration.
    Aslankurt M, Aslan L, Aksoy A, Erden B, Cekiç O.
    Eur J Ophthalmol; 2013 May; 23(4):553-7. PubMed ID: 23516253
    [Abstract] [Full Text] [Related]

  • 28. Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments.
    Heier JS.
    Ophthalmology; 2013 May; 120(5 Suppl):S23-5. PubMed ID: 23642783
    [Abstract] [Full Text] [Related]

  • 29. Cost comparison of ranibizumab and bevacizumab.
    Jackson TL, Kirkpatrick L.
    BMJ; 2011 Aug 23; 343():d5058. PubMed ID: 21862536
    [No Abstract] [Full Text] [Related]

  • 30. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.
    Ophthalmology; 2015 Aug 23; 122(8):1569-72. PubMed ID: 26038338
    [Abstract] [Full Text] [Related]

  • 31. Pharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumab.
    Kanoff J, Miller J.
    Semin Ophthalmol; 2013 Aug 23; 28(5-6):355-60. PubMed ID: 24010796
    [Abstract] [Full Text] [Related]

  • 32. How the comparison of age-related macular degeneration treatments trial results will impact clinical care.
    Davis J, Olsen TW, Stewart M, Sternberg P.
    Am J Ophthalmol; 2011 Oct 23; 152(4):509-14. PubMed ID: 21961847
    [Abstract] [Full Text] [Related]

  • 33. [Age-related visual loss].
    Neubauer AS, Kernt M.
    MMW Fortschr Med; 2013 Feb 07; 155(2):36-7. PubMed ID: 23573743
    [No Abstract] [Full Text] [Related]

  • 34. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF.
    Br J Ophthalmol; 2013 Apr 07; 97(4):454-9. PubMed ID: 23385630
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration.
    Roller AB, Amaro MH.
    Arq Bras Oftalmol; 2009 Apr 07; 72(5):677-81. PubMed ID: 20027409
    [Abstract] [Full Text] [Related]

  • 37. Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
    Scott AW, Bressler SB.
    Curr Opin Ophthalmol; 2013 May 07; 24(3):190-6. PubMed ID: 23492430
    [Abstract] [Full Text] [Related]

  • 38. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
    Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA.
    Am J Ophthalmol; 2011 Aug 07; 152(2):266-72. PubMed ID: 21664593
    [Abstract] [Full Text] [Related]

  • 39. Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    Aujla JS.
    Clin Exp Optom; 2012 Sep 07; 95(5):538-40. PubMed ID: 22621684
    [Abstract] [Full Text] [Related]

  • 40. Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.
    Moreno TA, Kim SJ.
    Semin Ophthalmol; 2016 Sep 07; 31(4):378-84. PubMed ID: 27116030
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.